Search

Background: Glomerular filtration rate (GFR) measurements are critical in patients with cancer. A variety of methods are used to calculate the estimated GFR. The aim of this study is to investigate whether there is a correlation between these methods and oncologic outcomes according to the stage and treatment agents. Methods: A total of 153 patients were retrospectively recruited. All GFR measurement methods was determined in all patients, before the first cycle of chemotherapy and before the subsequent administrations. Results: In the study population 40% of whom received platinum-based chemotherapy. In this group, overall survival was statistically significant in patients with a CKD-EPI creatinine value of 65 or greater (p:0.023). When we separated the arms according to the stage, there was no relationship between CKD-EPI Cystatin C and progression-free survival in metastatic patients (p: 0.13). In the non-metastatic group, median DFS was 7 months and OS was 13.9 months in patients with CKD-EPI Cystatine C level above 45 (p:0.005). Conclusions: Both CKD-EPI creatinine and CKD-EPI cystatin C were significantly associated with overall survival and diseasefree survival in patients receiving platinum-based chemotherapy. When assessed according to the stage, there was a general survival relationship with CKD-EPI cystatin C in the non-metastatic group and in the other groups there was no significant correlation with the estimated GFR measurements. [ABSTRACT FROM AUTHOR]

Objectives: Pulmonary giant cell carcinoma (PGCC) is a histological type of nonsmall cell lung cancer and classified as one of the five subtypes of sarcomatoid carcinoma of the lung. Pure PGCC is very rare. Material and Method: We represent our experience in the management of 7 patients (6 males and 1 female, with a range of 44-63 yr) with PGCC. The most representing symptoms were cough and hemoptysis. Upper lobectomy (n=7) and additionally mediastinal lymphadenectomy were performed in all patients. Results: Definitive histological examination confirmed the diagnosis of PGCC in all cases. Even though there was no perioperative mortality, postoperative complications developed in a case were hemorrhage in the early perioperative period and bronchus fistula after two months from the operation. The mean survival of the patients was estimated as 28.8 months (38 days - 116 months). Conclusion: The main treatment for PGCC is the complete surgical resection. Complete surgical resection was found to be usefull as a treatment of choice of PGCC in the early stage and contributed to survival. [ABSTRACT FROM AUTHOR]

Aim: The microtubule inhibitor eribulin mesylate anthracycline and taxane resistance have been accepted for use in patients with metastatic breast cancer. The goal is to investigate the efficacy of eribulin mesylate. Material and Methods: Retrospective study was carried out in Istanbul Okmeydanı educational and research hospital medical oncology clinic patients who were treated for metastatic breast cancer and who had received at least 2 serial chemotherapy including anthracycline and taksan. Results: A total of 25 patients were included in the study. Median age was 54.9 (range 36-73). Median follow-up time is 11.6 months. 68% of the patients were ER positive, 68% were Pr positive, 8.3% were HER2 positive and 6.2% were triple negative. 78% of the patients had liver, 64% had bone, and 36% had lung metastases. The treatement line number was 4.4 (min3-max6). The number of cycles of Eribulin was 6.6 (min 1-max 33). Median PFS is 6.6 (0-26) months and median OS is 17 (0-30). There were 8% complete response (2 patients), 12% (3 patients) partial response, 52% (13 patients) stable response and 28% (7 patients) progressive disease. there was no difference in survival according to patients' hormone receptor status and HER2 status (P = 0.187). There was no difference in survival according to the metastatic sites in the patients (P = 0.875). Grade 3 to 4 hematologic toxicity in 12% (3 patients) and grade 3-4 neuropathy in 4% (1 patient) in the patient, 40% (10 patients) grade 1-2 hematologic toxicity in the patient, grade 1-2 neuropathies were seen. Conclusion: Eribulin mesylate have been found to be effective and tolerable in line 3 and more than subsequent line in the treatment of patients with metastatic breast cancer who anthracycline and taksan resistance and previously received multiple line chemotherapy. [ABSTRACT FROM AUTHOR]

Despite the relevant progress achieved in the last 20 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In the late 1990s several professional organizations published recommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and radiotherapy. Besides nausea, additional problems of antiemetic therapy such as prophylaxis of cisplatin-induced delayed nausea and vomiting, nausea and vomiting induced by high-dose chemotherapy and nausea and vomiting induced by combined chemoradiation as well as antiemetics in children remain unsolved. Therefore, more research on these topics is necessary as is the development of new antiemetics, thereby leading to an improvement in quality of life in patients treated with chemotherapy and/or radiotherapy. [ABSTRACT FROM AUTHOR]

We report a rare case of primary carcinoma of the liver that presented with cavitary lesion in liver. 68 year-old woman was hospitalized with diagnosis of liver abscess, but histological examination was compatible with squamous cell carcinoma. Detailed radiological and clinical evaluation failed to reveal occult primary. Because patients' clinical signs, symptoms and laboratory values supportsevere sepsis syndrome, systemic chemotherapy was deferred. Though the case was treated with broad spectrum antibiotics and cavitary lesions were drained by intervention, the patient's condition deteriorated and we lost the case at the 20th day of admission. In conclusion, cavitation of tumor can be sign of highly aggressive biological behavior and poor prognosis, early diagnosis, surgical resection and starting effective chemotherapy in patients those who have good performance score may be equally important as supportive care. [ABSTRACT FROM AUTHOR]